Parkwood LLC Bei Gene, Ltd. Transaction History

Parkwood LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$129.52 - $174.32 $294,658 - $396,578	-2,275 Reduced 20.08%	9,055 $1.29 Million
Q1 2024 May 15, 2024	BUY	$141.8 - $181.47 $689,998 - $883,033	4,866 Added 75.28%	11,330 $1.77 Million
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $30,305 - $38,501	191 Added 3.04%	6,464 $1.17 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $50,003 - $62,586	278 Added 4.64%	6,273 $1.13 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $139,787 - $209,155	784 Added 15.05%	5,995 $1.07 Million
Q1 2023 May 15, 2023	BUY	$215.53 - $274.5 $121,343 - $154,543	563 Added 12.11%	5,211 $1.12 Million
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $143,332 - $261,860	-1,142 Reduced 19.72%	4,648 $1.02 Million
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $124,287 - $190,712	-943 Reduced 14.01%	5,790 $781,000
Q2 2022 Aug 15, 2022	SELL	$121.11 - $216.05 $34,395 - $61,358	-284 Reduced 4.05%	6,733 $7,000
Q1 2022 May 13, 2022	BUY	$146.52 - $269.56 $43,369 - $79,789	296 Added 4.4%	7,017 $1.32 Million
Q4 2021 Feb 11, 2022	SELL	$248.56 - $389.34 $81,030 - $126,924	-326 Reduced 4.63%	6,721 $1.82 Million
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $373,152 - $602,694	1,495 Added 26.93%	7,047 $2.56 Million
Q2 2021 Aug 13, 2021	BUY	$292.75 - $367.01 $165,989 - $208,094	567 Added 11.37%	5,552 $1.91 Million
Q1 2021 May 14, 2021	SELL	$260.64 - $382.12 $755,334 - $1.11 Million	-2,898 Reduced 36.76%	4,985 $1.74 Million
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $1.74 Million - $2.5 Million	7,883 New	7,883 $2.04 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.